Cannabinoids: for better and for worse

Thibaut, Florence; Hoehe, Margret R.

doi:10.31887/DCNS.2020.22.3/fthibaut

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Cannabinoids: for better and for worse

MPS-Authors

/persons/resource/persons50204

Hoehe, Margret R.
Diploid Genomics (Margret R. Hoehe), Dept. of Computational Molecular Biology (Head: Martin Vingron), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Thibaut_2020.pdf
(Publisher version), 235KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Thibaut, F., & Hoehe, M. R. (2020). Cannabinoids: for better and for worse. Dialogues in Clinical Neuroscience, 22(3), 201-204. doi:10.31887/DCNS.2020.22.3/fthibaut.

Cite as: https://hdl.handle.net/21.11116/0000-0007-60DD-4

Abstract

The use of cannabis as a drug has undergone a remarkable change of direction: considered as a symbol of countercultures in past decades, it is presently being hailed as a cure for any number of diseases and conditions. Thus, despite concerns about the safety of cannabis and cannabinoids, quite a few drugs that contain cannabinoids have recently been approved by several drug agencies, and the medicinal and recreational use of cannabis has been legalized in various countries and states. The promise of cannabinoids for therapeutic use, as well as potentially detrimental health risks and regulatory issues, will need to be carefully weighed. 